SOX2 and breast cancer: The expression levels of 166 targets of all three factors (Nanog, Oct4, and Sox2) clustered the PYK2 highly expressed basal-like BC patients separately from the PYK2 low-expressing patients (Fig 6F), demonstrating the clinical correlation between PYK2 expression and the activity of Nanog and Oct4 in those patients, and further highlighting the clinically relevance of our findings.